Page last updated: 2024-12-08
2-methyladenosine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2-methyladenosine : A methyladenosine in which the methyl group is located at position 2 on the adenine ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 459890 |
| CHEMBL ID | 608348 |
| CHEMBL ID | 2347288 |
| CHEBI ID | 19688 |
| SCHEMBL ID | 41422 |
| MeSH ID | M0097929 |
Synonyms (16)
| Synonym |
|---|
| (2r,3r,4s,5r)-2-(6-amino-2-methyl-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
| adenosine, 2-methyl- |
| 16526-56-0 |
| 2-methyladenosine |
| nsc 93499 |
| bdbm50368901 |
| chembl608348 |
| CHEBI:19688 , |
| m(2)a |
| CHEMBL2347288 |
| SCHEMBL41422 |
| 2-methyl adenosine |
| AKOS030568109 |
| (2r,3r,4s,5r)-2-(6-amino-2-methyl-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
| AMY31028 |
| (2r,3r,4s,5r)-2-(6-amino-2-methyl-9h-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| methyladenosine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | IC50 (µMol) | 8.0000 | 6.0000 | 7.3333 | 8.0000 | AID75705; AID75715; AID75727 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (17)
Molecular Functions (9)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity | Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) |
| protein binding | Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) |
| microtubule binding | Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) |
| aspartic-type endopeptidase inhibitor activity | Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) |
| peptidyl-cysteine S-nitrosylase activity | Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) |
| identical protein binding | Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) |
| NADP binding | Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) |
| NAD binding | Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) |
| disordered domain specific binding | Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (14)
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID75715 | Tested for the inhibitory activity against Glycosomal glyceraldehyde 3-phosphate dehydrogenase (gGAPDH) of Trypanosoma brucei | 1994 | Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21 | Selective inhibition of trypanosomal glyceraldehyde-3-phosphate dehydrogenase by protein structure-based design: toward new drugs for the treatment of sleeping sickness. |
| AID75727 | Tested for the inhibitory activity against Glycosomal glyceraldehyde 3-phosphate dehydrogenase (gGAPDH) of human erythrocyte | 1994 | Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21 | Selective inhibition of trypanosomal glyceraldehyde-3-phosphate dehydrogenase by protein structure-based design: toward new drugs for the treatment of sleeping sickness. |
| AID739929 | Cytotoxicity against african green monkey Vero cells by non-radioactive cell proliferation assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | 6-Oxo and 6-thio purine analogs as antimycobacterial agents. |
| AID740172 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition by radiometric BACTEC assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | 6-Oxo and 6-thio purine analogs as antimycobacterial agents. |
| AID75705 | Tested for the inhibitory activity against Glycosomal glyceraldehyde 3-phosphate dehydrogenase (gGAPDH) of Leishmania mexicana | 1994 | Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21 | Selective inhibition of trypanosomal glyceraldehyde-3-phosphate dehydrogenase by protein structure-based design: toward new drugs for the treatment of sleeping sickness. |
| AID739914 | Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 27294 | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | 6-Oxo and 6-thio purine analogs as antimycobacterial agents. |
| AID740174 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 6.25 ug/ml by radiometric BACTEC assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | 6-Oxo and 6-thio purine analogs as antimycobacterial agents. |
| AID244883 | Minimum inhibitory concentration against Mycobacterium tuberculosis | 2005 | Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7 | Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 31.20
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.20) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||